Drug Delivery Business

Frequency Therapeutics drug shows promise in restoring hearing in small study

By

Frequency Therapeutics updated logoFrequency Therapeutics (Woburn, Mass.) recently announced data related to its experimental FX-322 drug.

The small Phase 1/2 study, which was published in Otology & Neurotology, found hearing improvements in adults with age-related sensorineural hearing loss.

At present, there are no FDA-approved drugs for preventing or restoring such hearing loss, although administering steroids can facilitate recovery of hearing for some patients with sudden sensorineural hearing loss.

The Frequency Therapeutics study found that participants who received a single dose FX-322 had a statistically significant increase in word recognition.

Get the full story from our sister site, Drug Discovery & Development.

IN CASE YOU MISSED IT

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].